Navigation Links
Orexigen® Therapeutics Reports Third Quarter Financial Results
Date:11/8/2011

>Anticipated reduction in predicted 10-year cardiovascular risk among Contrave treated patients from the Phase 3 COR program using a variety of validated risk models.
  • An imaging study showing that Contrave activated regions of the brain involved in controlling the response to food cues.
  • New analyses from the COR-I and COR-BMOD Phase 3 studies highlighting weight loss among subjects completing one year of therapy.  

    • The Company continues to expect cash expenditures for the second half of 2011 to be substantially lower than for the first half of 2011. The Company does anticipate a substantial increase in planned expenditures in 2012 as the major activities for the CVOT get underway once the details of the protocol are finalized and a clinical research organization to execute the trial is engaged.  The Company plans to provide a more detailed update on the specifics of the trial as well as additional financial guidance in the first quarter of 2012.

    About ContraveContrave, an investigational combination therapy of naltrexone HCl and bupropion HCl, was studied for its ability to help people with obesity initiate and sustain weight loss of at least 5 percent of their starting body weight in one year. Contrave was submitted for U.S. regulatory approval in March 2010. The original submission was based on multiple clinical trials that evaluated Contrave in more than 4500 patients. Orexigen received a Complete Response letter from the FDA on January 31, 2011.

    About Orexigen Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Contrave has completed Phase 3 clinical trials, and the Company's other product candidate, Empatic(TM), has completed Phase 2 clinical trials. Each of the components of the Company's product candidates has already received regulatory approval and has been commercialized previously. Further information about the Company can be found at '/>"/>

    SOURCE Orexigen Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5

    Related biology technology :

    1. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
    2. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
    3. Orexigen® Therapeutics to Present at JP Morgan Healthcare Conference
    4. Orexigen® Therapeutics Announces Corporate Realignment
    5. Orexigen® Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
    6. Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring
    7. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
    8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
    9. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
    10. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
    11. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/24/2013)... May 24, 2013 The Oklahoma tornado ... following its ravage, the mayor of Moore, one of the ... houses, said a report from cnn.com. Reaching out to also ... complimentary Molderizer and Safe Shield to counter the looming mold ... published on May 22, 2013, caused 24 deaths, My Cleaning ...
    (Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") ... science-based research and development, sales and marketing of ... announced today that it is awarding exclusive Vestiage ... of Reluma Skin Illuminating Facial Care. Qualified applicants ... sending an email to info(at)vestiageinc(dot)com and putting RELUMA ...
    (Date:5/24/2013)... May 24, 2013 Quincy Bioscience, ... and development of calcium-binding proteins to support healthy ... safety assessment study of apoaequorin in ... published for the British Industrial Biological Research Association. ... to investigate potential adverse effects, if any, of ...
    (Date:5/23/2013)... England , May 24, 2013 ... Mundipharma angefertigt – Bei der ... , 91 % der Teilnehmer einer groß ... nur 20 % laut GINA [*] -Definition [1] ... dass Menschen mit Asthma generell einer von vier Denkweisen ...
    Breaking Biology Technology:Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7
    ... Australia, March 18 Phosphagenics,Limited ("Phosphagenics") (ASX: POH, ... panel ("the panel") of food safety experts,unanimously concluded ... Safe (GRAS). This comes as a result of ... the use of Phospha,E(R) in breakfast cereals, juice ...
    ... Calif., March 18 TorreyPines Therapeutics,Inc. (Nasdaq: ... Phase II study of,NGX267, a muscarinic agonist in ... syndrome., The company is conducting a randomized, ... to evaluate,the safety, tolerability and efficacy of this ...
    ... proprietary products that improve the, safety, effectiveness, and environmental ... existing and new denitrification ... ... (EOS) announced today that the company has closed the first,tranche of ...
    Cached Biology Technology:GRAS Status Opens Door to U.S. Food Industry 2GRAS Status Opens Door to U.S. Food Industry 3TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 3TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing 2Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing 3Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing 4
    (Date:5/22/2013)... life scientists provide important new details on how climate ... online May 21 in the Journal of Animal ... making accurate predictions and informing policymakers of how species ... , "There is a growing recognition among biologists ... one another, and that this is going to have ...
    (Date:5/22/2013)... of pollinating insects and wild plants have slowed in ... led by the University of Leeds and the Naturalis ... dramatic reductions in the diversity of species in Britain, ... , But the picture brightened markedly after 1990, with ... bees, hoverflies and wild plants. , Professor ...
    (Date:5/21/2013)... a long time that some creatures evolve more quickly ... plants. But it may be that height plays a ... the U. S. National Evolutionary Synthesis Center. , ... the journal Nature Communications , Lanfear and colleagues ... from a database of global patterns in plant height ...
    Breaking Biology News(10 mins):UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3Small but speedy: Short plants live in the evolutionary fast lane 2
    ... new technique for transplanting the ovaries of women who ... treatment was outlined to the 25th annual conference of ... (Monday 29 June). Dr. Pascal Piver, manager ... France, described a new, two-step method of ovarian transplant ...
    ... Netherlands: Analysis of the longest running ICSI programme in ... born from frozen embryos fertilised via ICSI (intracytoplasmic sperm ... frozen embryos fertilised via standard IVF treatment. The ... cycles in which the women had additional hormone medication ...
    ... aquarium fish don,t mind who or what they encounter in ... famously (but incorrectly) short memory is to be believed. Scientists ... research to show this is not the case and are ... , In line with the aim to establish welfare ...
    Cached Biology News:Ovarian transplantation: First baby is born after a new technique 2ICSI or IVF: Babies born from frozen embryos do just as well 2ICSI or IVF: Babies born from frozen embryos do just as well 3
    ... Biotin Streptavidin-AP Systems provide rapid, precise ... antigens in frozen or paraffin-embedded tissue, ... systems also facilitate double or triple ... performed simultaneously with primary antibodies of ...
    ... suitable for a broad range of applications. ... physiological signal such as ECG, EMG, SCR ... use with a wide range of bridge ... stimulus artefact clamp to avoid saturation when ...
    ... or 384-well PCR plates Dimples on both sides ... plates End tabs on Thermo-Mat™ 384 fit into ... sealing is achieved with either Thermo-Mat™ 96 or 384 ... lid thermal cyclers Fully autoclavable May ...
    ... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: barcoded, ...
    Biology Products: